Enjoy complimentary customisation on priority with our Enterprise License!
According to Technavio’s market research report, the global antipsychotic drugs market will grow at a CAGR of almost 2% during the forecast period. The introduction of enhanced next-generation products will drive the growth prospects for the market during the estimated period. The first-generation or typical antipsychotic drugs such as chlorpromazine, haloperidol, and fluphenazine were thought to produce extrapyramidal side-effects (EPSE). As a result, these drugs were discontinued and second-generation antipsychotic drugs were introduced. Clozapine, risperidone, olanzapine, quetiapine, and ziprasidone are second-generation antipsychotic drugs, which are also known as atypical antipsychotic drugs. Further research and developmental activities resulted in the introduction of Bristol-Myers Squibb's ABILIFY, which is referred to as a third-generation antipsychotic drug. This drug is used to treat schizophrenia and bipolar disorder and exhibits improved efficacy and lesser side effects. The introduction of such enhanced new antipsychotic drugs will boost growth in the market.
Based on the antipsychotic drugs industry analysis, the Americas dominated the global antipsychotic drugs market during 2016. The region is expected to grow at a moderate pace due to patent expiry of major drugs such as Geodon, Zyprexa, ABILIFY, SEROQUEL, and Prozac. However, the region will continue to dominate the market during the estimated period due to the introduction of NUPLAZID by Acadia Pharmaceuticals. This drug is highly popular in the treatment of most common symptoms of all mental disorders such as hallucination and delusion.
The global antipsychotic drugs market is highly fragmented and is characterized by the presence of several small and mid-sized players. These vendors are increasingly competing against each other based on factors such as emerging indications or applications, major patent expiries, and the rising prevalence of mental disorder in the developed and other developing countries. The patent expiry of major drugs such as Zyprexa and Seroquel will negatively influence the growth prospects of vendors. This, in turn, will create an opportunity for generic players to enter the market and strengthen the competitive environment of the market.
Key vendors in this market are
Other prominent vendors in the market include Actavis Generics, Alkermes, and Bristol-Myers Squibb.
The increasing incidence rate of schizophrenia is driving the use of antipsychotic drugs. Schizophrenia is an abnormal behavior and is characterized by the inability of an individual to make distinctions between assumptions and reality. The individual suffering from schizophrenia hears voices that are not real, develops a confused thinking, and experiences a lack of motivation and social engagement. In some cases, individuals acquire schizophrenia genetically. In other cases, exposure to cannabis, poor nutrition during pregnancy, and certain infections cause schizophrenia. The treatment of schizophrenia is administered by prescribing antipsychotic medications and this will stimulate growth in the segment.
According to the antipsychotic drugs market analysis, the second-generation antipsychotic drugs segment dominated the antipsychotic drugs market with the highest market shares. These drugs are preferred over first-generation antipsychotic drugs because they involve lesser side effects and are highly efficient in the treatment of various mental disorders. The adoption of these drugs is high because they reduce EPSE, controls symptoms, and maintains the normal levels of prolactin. This segment yields a high prescription value that in turn, will drive growth in the segment during the forecasted period.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Key clinical trials
PART 07: Market landscape
PART 08: Market segmentation by disease type
PART 09: Market segmentation based on MoA
PART 10: Geographical segmentation
PART 11: Decision framework
PART 12: Drivers and challenges
PART 13: Market trends
PART 14: Vendor landscape
PART 15: Key vendor analysis
PART 16: Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.